HRP20140675T1 - Elisa za vegf - Google Patents
Elisa za vegf Download PDFInfo
- Publication number
- HRP20140675T1 HRP20140675T1 HRP20140675TT HRP20140675T HRP20140675T1 HR P20140675 T1 HRP20140675 T1 HR P20140675T1 HR P20140675T T HRP20140675T T HR P20140675TT HR P20140675 T HRP20140675 T HR P20140675T HR P20140675 T1 HRP20140675 T1 HR P20140675T1
- Authority
- HR
- Croatia
- Prior art keywords
- reagent
- antibody
- vegf
- biological sample
- detecting
- Prior art date
Links
- 101100372758 Danio rerio vegfaa gene Proteins 0.000 title 1
- 101150030763 Vegfa gene Proteins 0.000 title 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 11
- 238000000034 method Methods 0.000 claims 9
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 8
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 8
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 8
- 239000012472 biological sample Substances 0.000 claims 6
- 238000001514 detection method Methods 0.000 claims 6
- 210000004408 hybridoma Anatomy 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 claims 1
- 230000000890 antigenic effect Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 239000006166 lysate Substances 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Claims (20)
1. Postupak in vitro za otkrivanje vaskularnog endotelnog faktora rasta (VEGF) oblika (VEGF110+) u biološkom uzorku, naznačen time, da obuhvaća sljedeće korake:
(a) kontakt i inkubacija biološkog uzorka sa zahvaćenim reagensom koji je imobiliziran na krutom nosaču, pri čemu taj zahvaćeni reagens je monoklonalno protutijelo 5C3 proizvedeno iz hibridoma 5C3.1.1 ATCC deponiranog pod brojem PTA-7737;
(b) odvajanje biološkog uzorka iz imobiliziranog zahvaćenog reagensa;
(c) kontakt imobiliziranog zahvaćenog reagensa – ciljanog molekularnog kompleksa s otkrivajućim protutijelom koje se veže na KDR-receptor i/ili FLT1-receptor domene vezanja od VEGF ili koje se veže na epitop u VEGF 1-110; i
(d) mjerenje razine VEGF110+ spojenog na zahvaćeni reagens uporabom sredstva za detekciju za otkrivajuće protutijelo.
2. Postupak prema zahtjevu 1, naznačen time, da se biološki uzorak izolira iz ljudskog pojedinca.
3. Postupak prema zahtjevu 2, naznačen time, da ljudski pojedinac je vaskularni pacijent, dijabetički pacijent ili pacijent koji boluje od raka, a korak (d) nadalje obuhvaća usporedbu sa standardnom krivuljom za određivanje razine VEGF u usporedbi s istom kod zdravog pojedinca.
4. Postupak prema zahtjevu 1, naznačen time, da biološki uzorak je tumorski lizat, plazma, serum ili urin.
5. Postupak prema zahtjevu 1, naznačen time, da se imobilizirani zahvaćeni reagens oblaže na mikrotiterskoj ploči.
6. Postupak prema zahtjevu 1, naznačen time, da otkrivajuće protutijelo je takvo protutijelo koje se može izravno otkriti.
7. Postupak prema zahtjevu 6, naznačen time, da otkrivajuće protutijelo se pojačava s fluorimetričkim reagensom.
8. Postupak prema zahtjevu 7, naznačen time, da otkrivajuće protutijelo se biotinilira, a sredstvo za detekciju je avidin-peroksidaza ili streptavidin-peroksidaza i 3,3’,5,5’-tetrametil benzidin.
9. Postupak prema zahtjevu 1, naznačen time, da otkrivajuće protutijelo je MAb A4.6.1.
10. Imunoanalitička garnitura za otkrivanje VEGF110+ u biološkom uzorku, naznačena time, da garnitura obuhvaća:
(a) monoklonalno protutijelo 5C3 proizvedeno pomoću hibridoma 5C3.1.1 ATCC deponiranog pod brojem PTA-7737, kao zahvaćeni reagens; i
(b) otkrivajuće protutijelo koje se veže na KDR-receptor i/ili FLT1-receptor domene vezanja od VEGF ili koje se veže na epitop u VEGF 1-110, kao detekcijski reagens.
11. Garnitura prema zahtjevu 10, naznačena time, da nadalje obuhvaća kruti nosač za zahvaćeni reagens.
12. Garnitura prema zahtjevu 11, naznačena time, da je zahvaćeni reagens imobiliziran na krutom nosaču.
13. Garnitura prema zahtjevu 12, naznačena time, da je zahvaćeni reagens obložen na mikrotiterskoj ploči.
14. Garnitura prema zahtjevu 13, naznačena time, da nadalje obuhvaća sredstvo za detekciju za otkrivanje protutijela.
15. Garnitura prema zahtjevu 14, naznačena time, da sredstvo za detekciju je kolorimetričko.
16. Garnitura prema zahtjevu 10, naznačena time, da nadalje obuhvaća pročišćeni VEGF kao antigenski standard.
17. Garnitura prema zahtjevu 10, naznačena time, da otkrivajuće protutijelo je MAb A4.6.1.
18. Protutijelo 5C3, naznačeno time, da se može dobiti ili proizvesti pomoću hibridoma 5C3.1.1 deponiranog pod brojem PTA-7737.
19. Protutijelo prema zahtjevu 18, naznačeno time, da je konjugirano na oznaku koja se može otkriti.
20. Hibridom 5C3.1.1, naznačen time, da je deponiran u ATCC pod brojem uloška PTA-7737.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82820306P | 2006-10-04 | 2006-10-04 | |
| PCT/US2007/080310 WO2008060777A2 (en) | 2006-10-04 | 2007-10-03 | Elisa for vegf |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20140675T1 true HRP20140675T1 (hr) | 2014-10-10 |
Family
ID=39301650
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20140675TT HRP20140675T1 (hr) | 2006-10-04 | 2014-07-15 | Elisa za vegf |
Country Status (25)
| Country | Link |
|---|---|
| US (5) | US20080227119A1 (hr) |
| EP (3) | EP3103812B1 (hr) |
| JP (1) | JP6025294B2 (hr) |
| KR (2) | KR101720887B1 (hr) |
| CN (2) | CN101523220B (hr) |
| AR (2) | AR063125A1 (hr) |
| AU (1) | AU2007319654B2 (hr) |
| BR (1) | BRPI0715239A2 (hr) |
| CA (1) | CA2663012C (hr) |
| DK (2) | DK2069798T3 (hr) |
| ES (2) | ES2470682T3 (hr) |
| HK (3) | HK1130090A1 (hr) |
| HR (1) | HRP20140675T1 (hr) |
| HU (1) | HUE030082T2 (hr) |
| IL (1) | IL197374A (hr) |
| MX (2) | MX2009003562A (hr) |
| NZ (1) | NZ613646A (hr) |
| PL (2) | PL2457929T3 (hr) |
| PT (1) | PT2069798E (hr) |
| RS (1) | RS53387B (hr) |
| RU (2) | RU2517301C2 (hr) |
| SI (2) | SI2069798T1 (hr) |
| TW (2) | TWI541251B (hr) |
| WO (1) | WO2008060777A2 (hr) |
| ZA (1) | ZA200901518B (hr) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050009110A1 (en) * | 2003-07-08 | 2005-01-13 | Xiao-Jia Chang | Methods of producing antibodies for diagnostics and therapeutics |
| ZA200901518B (en) | 2006-10-04 | 2010-05-26 | Genentech Inc | Elisa for VEGF |
| WO2011031986A1 (en) | 2009-09-10 | 2011-03-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer, National Institutes Of Health | Assays for soluble il-15 receptor alpha |
| JP2013538338A (ja) * | 2010-07-19 | 2013-10-10 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 抗癌治療への応答可能性の増大した患者を同定する方法 |
| AU2011281701A1 (en) * | 2010-07-19 | 2013-01-31 | F. Hoffmann-La Roche Ag | Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy |
| CN102207504A (zh) * | 2011-03-23 | 2011-10-05 | 北京华创远航科技有限公司 | 一种酶联检测试剂盒及其制备方法 |
| CN102435743B (zh) * | 2011-09-15 | 2014-10-15 | 北京健平九星生物医药科技有限公司 | 一种酶联检测试剂盒及其制备方法 |
| CN102426240B (zh) * | 2011-09-19 | 2014-10-15 | 北京健平金星生物科技有限公司 | 一种酶联检测试剂盒及其制备方法 |
| RU2633488C2 (ru) | 2011-12-19 | 2017-10-12 | Ф. Хоффманн-Ля Рош Аг | Способ определения свободного связывающего партнера мультиспецифичного связующего |
| WO2013106765A1 (en) | 2012-01-13 | 2013-07-18 | Genentech, Inc. | Biological markers for identifying patients for treatment with vegf antagonists |
| BR112014017630A8 (pt) * | 2012-02-01 | 2017-07-11 | Hoffmann La Roche | Métodos para a determinação de presença e/ou da quantidade de um antígeno |
| CN102645530B (zh) * | 2012-04-06 | 2014-06-18 | 上海蓝怡科技有限公司 | 甲状腺素酶联免疫体外诊断试剂盒中酶结合物稀释液的制备方法 |
| ES2627482T3 (es) | 2012-07-13 | 2017-07-28 | F. Hoffmann-La Roche Ag | Procedimiento para la detección de una proteína de unión multiespecífica |
| BR112016004437A2 (pt) | 2013-09-13 | 2017-10-17 | Genentech Inc | métodos de imunoteste e de seleção de linhagem de células, anticorpos e kit |
| AU2014318615B2 (en) | 2013-09-13 | 2020-03-12 | Genentech, Inc. | Methods and compositions comprising purified recombinant polypeptides |
| CA2927708C (en) | 2013-10-17 | 2021-05-25 | Sartar Therapeutics Ltd | Compositions comprising phosphodiesterase inhibitors for use in the treatment of a solid tumor in a human patient |
| RU2589286C1 (ru) * | 2015-02-03 | 2016-07-10 | Федеральное государственное бюджетное научное учреждение "Томский научно-исследовательский институт онкологии" (Томский НИИ онкологии) | Способ прогнозирования исхода заболевания у больных метастатическим раком почки |
| RU2622005C2 (ru) * | 2015-11-24 | 2017-06-08 | Федеральное государственное бюджетное учреждение "Государственный научный центр дерматовенерологии и косметологии" Минздрава России (ФГБУ ГНЦДК Минздрава России) | СПОСОБ ПОЛУЧЕНИЯ СЕЛЕКТИВНОГО ИММУНОСОРБЕНТА ДЛЯ УДАЛЕНИЯ АНТИТЕЛ-IgG К ДЕСМОГЛЕИНУ 3 ТИПА ИЗ СЫВОРОТКИ КРОВИ БОЛЬНЫХ ПУЗЫРЧАТКОЙ |
| CN105510595A (zh) * | 2015-12-01 | 2016-04-20 | 邹检平 | 基于量子点CdTe检测人血清中VEGF浓度的试剂盒及其使用方法 |
| WO2018011344A1 (en) | 2016-07-15 | 2018-01-18 | F. Hoffmann-La Roche Ag | Method and means for detecting the level of total vegf-a |
| CN107167588A (zh) * | 2017-03-28 | 2017-09-15 | 马杰 | 用于检测血清中血管内皮生长因子的抗体及试剂盒 |
| RU2732013C1 (ru) * | 2019-12-11 | 2020-09-10 | Федеральное бюджетное учреждение науки "Государственный научный центр прикладной микробиологии и биотехнологии" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ПМБ) | Способ сенсибилизации планшета для иммуноферментного анализа нерастворимыми белковыми антигенами |
| CN111044734A (zh) * | 2019-12-30 | 2020-04-21 | 上海复星长征医学科学有限公司 | 一种用于检测血管内皮生长因子的检测试剂盒及其制备方法和使用方法 |
| KR102676458B1 (ko) | 2021-05-20 | 2024-06-19 | 대한민국 | 보툴리눔 독소 a에 특이적인 항체, 이를 생산하는 하이브리도마 세포주, 및 이를 이용한 보툴리눔 독소 a 진단 키트 |
| CN117805397A (zh) * | 2024-02-29 | 2024-04-02 | 军科正源（北京）药物研究有限责任公司 | 检测游离vegf的方法 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE337223B (hr) | 1967-05-23 | 1971-08-02 | Pharmacia Ab | |
| US3720760A (en) | 1968-09-06 | 1973-03-13 | Pharmacia Ab | Method for determining the presence of reagin-immunoglobulins(reagin-ig)directed against certain allergens,in aqueous samples |
| FR2046920B1 (hr) | 1969-06-19 | 1974-05-03 | Citizen Watch Co Ltd | |
| US3691016A (en) | 1970-04-17 | 1972-09-12 | Monsanto Co | Process for the preparation of insoluble enzymes |
| US3940475A (en) | 1970-06-11 | 1976-02-24 | Biological Developments, Inc. | Radioimmune method of assaying quantitatively for a hapten |
| CA1023287A (en) | 1972-12-08 | 1977-12-27 | Boehringer Mannheim G.M.B.H. | Process for the preparation of carrier-bound proteins |
| US4195128A (en) | 1976-05-03 | 1980-03-25 | Bayer Aktiengesellschaft | Polymeric carrier bound ligands |
| US4330440A (en) | 1977-02-08 | 1982-05-18 | Development Finance Corporation Of New Zealand | Activated matrix and method of activation |
| CA1093991A (en) | 1977-02-17 | 1981-01-20 | Hideo Hirohara | Enzyme immobilization with pullulan gel |
| US4229537A (en) | 1978-02-09 | 1980-10-21 | New York University | Preparation of trichloro-s-triazine activated supports for coupling ligands |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| MX9204374A (es) | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
| US6020473A (en) * | 1995-08-25 | 2000-02-01 | Genentech, Inc. | Nucleic acids encoding variants of vascular endothelial cell growth factor |
| US7005505B1 (en) * | 1995-08-25 | 2006-02-28 | Genentech, Inc. | Variants of vascular endothelial cell growth factor |
| DE19532347A1 (de) | 1995-09-04 | 1997-03-06 | Bayer Ag | 4-Thiocarbamoyl-1-(3-pyrazolyl)-pyrazole |
| US6750044B1 (en) * | 1996-10-17 | 2004-06-15 | Genentech, Inc. | Variants of vascular endothelial cell growth factor having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids |
| CA2286330C (en) | 1997-04-07 | 2008-06-10 | Genentech, Inc. | Anti-vegf antibodies |
| JP3591264B2 (ja) * | 1997-12-24 | 2004-11-17 | 富士レビオ株式会社 | Ｖｅｇｆ１２１特異的モノクローナル抗体及び測定方法 |
| US7078382B1 (en) * | 1999-11-02 | 2006-07-18 | Genentech, Inc. | Modulation of eNOS activity and therapeutic uses thereof |
| KR100749982B1 (ko) * | 1999-11-16 | 2007-08-16 | 제넨테크, 인크. | 혈관 내피 성장 인자용 ｅｌｉｓａ |
| RU2271010C2 (ru) * | 2004-03-31 | 2006-02-27 | Общество с ограниченной ответственностью "Фирма МонА" | Способ иммуноферментного анализа для определения фактора виллебранда, моноклональное антитело к фактору виллебранда (варианты) и штамм гибридных культивируемых клеток животных mus. musculus l. - продуцент моноклональных антител к фактору виллебранда (варианты) |
| EP1866441A4 (en) * | 2005-03-24 | 2009-11-11 | Beth Israel Hospital | METHODS FOR DIAGNOSING FETAL TRISOMY 13 OR FETAL TRISOMA RISK 13 DURING PREGNANCY |
| ZA200901518B (en) | 2006-10-04 | 2010-05-26 | Genentech Inc | Elisa for VEGF |
-
2007
- 2007-10-03 ZA ZA200901518A patent/ZA200901518B/en unknown
- 2007-10-03 PL PL11189401.0T patent/PL2457929T3/pl unknown
- 2007-10-03 HU HUE11189401A patent/HUE030082T2/en unknown
- 2007-10-03 ES ES07868362.0T patent/ES2470682T3/es active Active
- 2007-10-03 MX MX2009003562A patent/MX2009003562A/es unknown
- 2007-10-03 US US11/866,560 patent/US20080227119A1/en not_active Abandoned
- 2007-10-03 EP EP16167119.3A patent/EP3103812B1/en active Active
- 2007-10-03 DK DK07868362T patent/DK2069798T3/da active
- 2007-10-03 DK DK11189401.0T patent/DK2457929T3/en active
- 2007-10-03 AR ARP070104393 patent/AR063125A1/es active IP Right Grant
- 2007-10-03 BR BRPI0715239-6A2A patent/BRPI0715239A2/pt active Search and Examination
- 2007-10-03 KR KR1020157005110A patent/KR101720887B1/ko active IP Right Grant
- 2007-10-03 RU RU2009116611/15A patent/RU2517301C2/ru active
- 2007-10-03 JP JP2009531581A patent/JP6025294B2/ja active Active
- 2007-10-03 SI SI200731464T patent/SI2069798T1/sl unknown
- 2007-10-03 KR KR1020097009095A patent/KR101551984B1/ko active IP Right Grant
- 2007-10-03 CA CA2663012A patent/CA2663012C/en active Active
- 2007-10-03 ES ES11189401.0T patent/ES2584322T3/es active Active
- 2007-10-03 CN CN200780036803.0A patent/CN101523220B/zh active Active
- 2007-10-03 PT PT78683620T patent/PT2069798E/pt unknown
- 2007-10-03 SI SI200731810A patent/SI2457929T1/sl unknown
- 2007-10-03 NZ NZ61364607A patent/NZ613646A/en unknown
- 2007-10-03 TW TW102139875A patent/TWI541251B/zh active
- 2007-10-03 PL PL07868362T patent/PL2069798T3/pl unknown
- 2007-10-03 EP EP07868362.0A patent/EP2069798B1/en active Active
- 2007-10-03 WO PCT/US2007/080310 patent/WO2008060777A2/en active Application Filing
- 2007-10-03 AU AU2007319654A patent/AU2007319654B2/en active Active
- 2007-10-03 TW TW96137100A patent/TWI429654B/zh active
- 2007-10-03 CN CN201310406549.6A patent/CN103454434B/zh active Active
- 2007-10-03 EP EP11189401.0A patent/EP2457929B1/en active Active
- 2007-10-03 RS RSP20140350 patent/RS53387B/en unknown
-
2009
- 2009-03-03 IL IL197374A patent/IL197374A/en active IP Right Grant
- 2009-04-02 MX MX2014011461A patent/MX342791B/es unknown
- 2009-10-16 HK HK09109608A patent/HK1130090A1/xx unknown
- 2009-10-16 HK HK12108559.2A patent/HK1168361A1/zh unknown
-
2010
- 2010-06-17 US US12/817,827 patent/US8449885B2/en active Active
-
2012
- 2012-10-25 US US13/660,563 patent/US9146245B2/en active Active
-
2014
- 2014-02-05 RU RU2014104113/15A patent/RU2014104113A/ru not_active Application Discontinuation
- 2014-07-15 HR HRP20140675TT patent/HRP20140675T1/hr unknown
-
2015
- 2015-07-30 US US14/814,139 patent/US9625462B2/en active Active
-
2017
- 2017-02-08 AR ARP170100313A patent/AR107561A2/es unknown
- 2017-03-13 US US15/456,846 patent/US20170276683A1/en not_active Abandoned
- 2017-06-13 HK HK17105832.2A patent/HK1232236A1/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20140675T1 (hr) | Elisa za vegf | |
| Waterboer et al. | Suppression of non-specific binding in serological Luminex assays | |
| EP3425406B1 (en) | Method for measuring lipoprotein's capacity to accept cholesterol and reagent kit | |
| RU2008136193A (ru) | Детектирование рака по повышенным уровням bcl-2 | |
| MX344053B (es) | Metodos para determinar isotipos de anticuerpos anti-farmacos. | |
| He et al. | Analytical platform evaluation for quantification of ERG in prostate cancer using protein and mRNA detection methods | |
| CA2554801A1 (en) | Method of detecting analyte using magnetic beads | |
| FR2935384B1 (fr) | Procede de detection du virus de la rougeole, dispositif et kit utilisant ce procede | |
| US8981066B2 (en) | Epigenetic mechanisms related to DNA damage and aging | |
| Zhang et al. | Novel high-throughput cell-based hybridoma screening methodology using the Celigo Image Cytometer | |
| Shim et al. | Persistence of the neutralizing antibody response after SARS-CoV-2 infection | |
| EP1214447B8 (de) | Nachweis des pyruvatkinase-isoenzyms im stuhl | |
| US20160025753A1 (en) | Assay for cannabinoids and methods of use thereof | |
| AU2011315244A8 (en) | Assay device | |
| WO2004081025A3 (en) | Differential megaplex immunoassay | |
| WO2006004958A3 (en) | Detection or measurement of antibodies to antigenic proteins in biological tissues or samples | |
| JP5456056B2 (ja) | 体液中のｉｆｉ１６の検出 | |
| US20090029394A1 (en) | Novel Assay for the Detection of an Antibody Bound to a Cell Membrane Receptor | |
| DE60038557D1 (en) | Assay | |
| Pyun et al. | Performance characteristic of anti-cyclic citrullinated peptide (CCP) assay on Korean rheumatoid arthritis (RA) patients and healthy controls | |
| RU2011146108A (ru) | Набор реагентов для иммуноферментного определения антител к эндогенным биорегуляторам в сыворотке крови для оценки иммунного статуса и выявления заболеваний зависимости | |
| US20220341943A1 (en) | Xbp1 isoform multiplex assay | |
| NZ597336A (en) | Elisa for vegf | |
| CN117999482A (zh) | 用于测定信号扩增的方法、组合物和试剂盒 | |
| AU2016232223A1 (en) | Materials and methods for detecting androgen receptor splice variants and uses thereof |